Employees: 13
Size Nuvectis Pharma (NVCT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $698M, the 2459th largest of 3,085 United States companies the cockpit tracks. Shares closed at $20.29 on 18 Nov 2026.
Performance Over six months the shares gained 90.9%, against -10.1% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $0 | $0 | $0 | $0 | $0 |
| EBITDA | -$52.1M | -$27.6M | -$19.8M | -$22.9M | -$19.2M |
| Net income | -$50.5M | -$28.9M | -$19.0M | -$22.3M | -$19.1M |
| Free cash flow | -$40.3M | -$16.0M | -$12.2M | -$16.0M | -$13.6M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Total debt | $0 | $0 | $0 | $0 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NVCT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.5% | -5.6% | 8th highest of 21 |
| 6-month return | +90.9% | -10.1% | highest of 21 |
| Distance from 52-week high | -30.7% | -34.0% | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | 0.6× | 4.0% | +5.3% |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 0.5× | -1.6% | -1.8% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 2.5× | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 0.8× | n/a | n/a |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | 0.3× | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | 1.6× | -8.3% | -2.8% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 2.6× | -4.8% | +6.4% |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 1.7× | n/a | n/a |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 0.9× | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 6.7× | 31.9% | +19.8% |
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 3.9× | n/a | n/a |
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | 16.1× | 42.7% | -0.9% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $727M | -9% | +8% | 26% | 3.8× | 5.9% | +11.3% |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 1.1× | -11.8% | +1.9% |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | 2.5× | n/a | n/a |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $738M | -20% | -5% | 13% | 1.8× | -2.0% | +26.1% |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | 2.4× | 25.2% | +10.3% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | 1.4× | -2.1% | 0.0% |